Wang et al. investigated the lncRNA signature for predicting recurrence among ER+ BC patients that were treated with tamoxifen using cohorts from Gene Expression Omnibus (GEO) (n = 298) and The Cancer Genome Atlas (TCGA) (n = 160), as training and validation cohort, respectively [127]. This evidence concerns the gene ESR1 and breast cancer.